Drug Overview: Vraylar

  • ID: 4533526
  • Report
  • 38 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics have full antagonistic activity at D2 and 5-HT2A receptors, giving cariprazine a unique pharmacology among drugs in the class.

Vraylar was initially developed as a drug for schizophrenia and bipolar disorder, and is now being investigated for the adjunctive treatment of major depressive disorder (MDD) as a line extension. Allergan has so far completed a single Phase III trial in MDD, which yielded negative data. Vraylar was first approved by the US Food and Drug Administration in September 2015.
Note: Product cover images may vary from those shown
2 of 3
OVERVIEW
Drug Overview
Product Profiles
Vraylar: Bipolar disorder
Vraylar: Schizophrenia
Vraylar: Depression

List of Figures
Figure 1: Vraylar for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Vraylar in bipolar disorder
Figure 3: Drug assessment summary for Vraylar in bipolar disorder
Figure 4: Vraylar for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Vraylar for schizophrenia
Figure 6: Drug assessment summary of Vraylar for schizophrenia
Figure 7: Vraylar sales for schizophrenia across the US and five major EU markets, by country, 2017-26
Figure 8: Vraylar for depression - SWOT analysis
Figure 9: Drug assessment summary for Vraylar in depression
Figure 10: Drug assessment summary for Vraylar in depression

List of Tables
Table 1: Vraylar bipolar disorder indication approvals
Table 2: Vraylar drug profile
Table 3: Overview of key pivotal trial data for Vraylar in bipolar disorder
Table 4: Key side effects (=5%) reported in clinical trials of Vraylar monotherapy for bipolar mania
Table 5: Vraylar Phase III trials in bipolar depression
Table 6: Vraylar drug profile
Table 7: Vraylar pivotal trial data in schizophrenia
Table 8: Vraylar other late-phase trial data in schizophrenia
Table 9: Vraylar sales for schizophrenia across the US and five major EU markets, by country ($m), 2017-26
Table 10: Vraylar drug profile
Table 11: Vraylar Phase II and III data in depression
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll